Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hikma Pharmaceuticals ( (GB:HIK) ) just unveiled an update.
Hikma Pharmaceuticals has continued executing its $250 million share buyback programme, repurchasing 233,110 ordinary shares between 30 March and 2 April 2026 on the London Stock Exchange and Cboe Europe at prices mainly between 1,237p and 1,284p. The company plans to cancel these shares, and since launching the programme in late February it has acquired nearly 4.0 million shares for £49.8 million, reducing its free float to 217,892,329 shares and marginally boosting earnings per share and capital returns for investors.
Following the latest transactions, Hikma now holds 12,833,233 shares in treasury, with the total voting rights standing at 217,892,329, a figure investors will use for calculating holdings and regulatory thresholds. The ongoing repurchases underscore management’s confidence in the company’s valuation and balance sheet strength, while modestly tightening the stock’s supply in the market and reinforcing shareholder-focused capital allocation.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £1800.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on HIK Stock
According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational generics and specialty pharmaceuticals company listed in London and on Nasdaq Dubai. It develops, manufactures and markets a broad portfolio of injectable and oral medicines, with a particular focus on supplying high-quality affordable treatments to hospitals and healthcare systems in the U.K., MENA region and global markets.
Average Trading Volume: 1,362,833
Technical Sentiment Signal: Sell
Current Market Cap: £2.83B
See more insights into HIK stock on TipRanks’ Stock Analysis page.